1. Generics Bulletin
  2. >>Products
  3. >>Generics

Draft Bottleneck Bill Must Go Further, Urges German Generics Body

Only Targeting Antibiotics And Oncology Will Not Solve Shortages Issue

 
• By Chloe Kent

The German government has released a draft bill to remedy supply chain bottlenecks for antibiotic and oncology drugs, but Pro Generika, the country’s trade association for off-patent drugs, has urged it to apply these proposed changes to all generic medicines.

German flag outside of the Reichstag in Berlin
German draft law centers on antibiotics and oncology • Source: Shutterstock

German generics trade association Pro Generika has called for a draft bill from the country’s federal ministry for health, Bundesministerium für Gesundheit, to go further in addressing the impact of supply chain bottlenecks on the German market. The current draft only addresses antibiotic and oncology medicines, which Pro Generika says make up just 1.1% of all daily therapy doses.

Bork Bretthauer, managing director of Pro Generika, said: “Politicians have recognized that prioritizing cheap generics has destabilized supply and is leading to bottlenecks

More from Generics

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

More from Products

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.